Research and Markets: Global PCOS (Stein-Leventhal Syndrome) Drugs Market 2014-2018

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/t4sbkt/global_pcos_drugs) has announced the addition of the "Global PCOS Drugs Market 2014-2018" report to their offering.

The analysts forecast the Global PCOS Drugs market will grow at a CAGR of 2.665% over the period 2013-2018.

PCOS, also known as Stein-Leventhal Syndrome, is one of the most common hormonal endocrine disorders in women. It is characterized by polycystic ovaries, irregular or no menstrual periods, irregular ovulation, and high levels of androgens (male hormones) in the body. The exact cause of PCOS is unknown. In PCOS, small cysts form on the ovaries, which do not produce a sufficient amount of hormone to initiate ovulation. The ovarian follicles, which are filled with fluid in preparation for ovulation, remain as cysts when ovulation does not occur. Lifestyle modifications, medication, and surgery are some of the currently available treatments for PCOS.

This report covers the present scenario and the growth prospects of the Global PCOS Drugs market for the period 2014-2018. To calculate the market size, the report considers the revenue generated through the sales of marketed, off-label, and generic drugs used in the treatment of PCOS.

The report, the Global PCOS Drugs Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global PCOS Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Vendors

  • Bristol Myers Squibb Co.
  • Merck & Co. Inc.
  • Novartis AG
  • Sanofi SA
  • Teva Pharmaceutical Inc.

Other Prominent Vendors

  • AstraZeneca plc
  • Catalysis SL
  • Crinetics Pharmaceuticals Inc.
  • Dexa Medica Group
  • EffRx Inc.
  • Neurocrine Biosciences Inc.

Market Drivers/Challenges/Trends

  • Increase in Patient Population.
  • Lack of Approved Drugs.
  • Increase in Awareness of PCOS Drugs.

Key Questions Answered in this Report

  • What will the market size be in 2018 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

For more information visit http://www.researchandmarkets.com/research/t4sbkt/global_pcos_drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals